Floatz logo

Cmvpp65-A*0201 Peptide Vaccine

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

City of Hope Medical CentervaccinePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

86 Active assets in the Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BBB
Nilotinib
Novartis Pharmaceuticals
Phase 4BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BBB
Sargramostim
Virginia Commonwealth University
Phase 2BBB
METHOTREXATE
M.D. Anderson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

Cmvpp65-A*0201 Peptide Vaccine is also rated in:

adult acute lymphoblastic leukemiaDormant
B
Indicative ·
57 / 100
View asset →
Hodgkins lymphomaDormant
B
Indicative ·
57 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →